Biochanin A

Biochanin A at a Glance

Biochanin A is the dominant O-methylated isoflavone of red clover (Trifolium pratense) and a major isoflavone of chickpea. Structurally it is 4’-methylgenistein — genistein carrying an extra methyl group on the B-ring — and that one difference is the key to the whole molecule: in the body biochanin A is O-demethylated to genistein, so it behaves partly as a natural precursor of the stronger phytoestrogen ^{1,2Reference 1Wang Y et al. · 2008In vitroThe red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression — in vitroView study →Reference 2Tolleson WH et al. · 2002In vitroMetabolism of biochanin A and formononetin by human liver microsomes in vitroView study →}.

It is a weak phytoestrogen, and this is its most familiar role: biochanin A is one of the isoflavones in the red-clover extracts marketed for menopausal symptoms ^{7Reference 7Kanadys W et al. · 2021Meta-analysisEvaluation of clinical meaningfulness of red clover (Trifolium pratense L.) extract to relieve hot flushes and menopausal symptoms in peri- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trialsView study →}. Beyond the estrogen receptor it has a scattered but interesting preclinical pharmacology — aromatase inhibition (a distinct anti-cancer mechanism from genistein’s) ^{1Reference 1Wang Y et al. · 2008In vitroThe red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression — in vitroView study →}, anti-inflammatory and analgesic activity that runs partly through an unusual endocannabinoid route ^{3,4Reference 3Thors L et al. · 2010Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolaseView study →Reference 4Zada W et al. · 2022Fatty acid amide hydrolase inhibition and N-arachidonoylethanolamine modulation by isoflavonoids: a novel target for upcoming antidepressantsView study →}, neuroprotection in Parkinson’s-disease models ^{8,9Reference 8Chen HQ et al. · 2007In vitroBiochanin A protects dopaminergic neurons against lipopolysaccharide-induced damage through inhibition of microglia activation and proinflammatory factors generation — rat / in vitroView study →Reference 9Wang J et al. · 2016In vitroBiochanin A protects against lipopolysaccharide-induced damage of dopaminergic neurons both in vivo and in vitro via inhibition of microglial activationView study →}, and metabolic/antidiabetic effects ^{10Reference 10Oza MJ · 2018AnimalBiochanin A improves insulin sensitivity and controls hyperglycemia in type 2 diabetes — rat in vivoView study →}.

The honest frame for the page: apart from whole-red-clover human trials, this is an isolated-molecule, mostly-rodent literature. Biochanin A’s oral bioavailability is poor (single-digit percent in rats) and much of an oral dose is demethylated or conjugated before it acts ^{5Reference 5Moon YJ · 2007AnimalPharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in ratsView study →}, so the micromolar effects seen in cell culture do not map cleanly onto human intake.

Biochanin A & Genistein: The Methyl-Ether Precursor

The single most important fact about biochanin A is its relationship to genistein. Biochanin A is genistein with a methyl group on the 4’-hydroxyl — the 4’-methyl ether — and in the body that methyl group is removed. Human liver microsomes O-demethylate biochanin A to genistein, a reaction driven mainly by cytochrome-P450 enzymes, alongside hydroxylation to other metabolites ^{2Reference 2Tolleson WH et al. · 2002In vitroMetabolism of biochanin A and formononetin by human liver microsomes in vitroView study →}; the conversion was first observed in the rat in the early 1960s. So oral biochanin A is, in part, a slow-release source of genistein.

This exactly parallels its sibling: formononetin is the 4’-methyl ether of daidzein and is demethylated to daidzein in vivo. Red clover carries the methylated pair (biochanin A + formononetin) as its dominant isoflavones, with the demethylated genistein/daidzein present only in traces natively — the active phytoestrogens are substantially generated from the methyl ethers after ingestion ^{7Reference 7Kanadys W et al. · 2021Meta-analysisEvaluation of clinical meaningfulness of red clover (Trifolium pratense L.) extract to relieve hot flushes and menopausal symptoms in peri- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trialsView study →}.

The methyl ether is not merely a masked genistein, though. It has its own pharmacology while intact — most cleanly in aromatase inhibition, where the methyl group is decisive. In breast-cancer cells biochanin A inhibited both aromatase (CYP19) enzyme activity and its expression, whereas genistein suppressed only expression; the 4’-methoxy group is thought to create steric hindrance in the enzyme’s active site that the free 4’-OH of genistein lacks ^{1Reference 1Wang Y et al. · 2008In vitroThe red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression — in vitroView study →}. In other words, demethylation trades one activity for another: the intact ether is the better aromatase blocker, its genistein metabolite the stronger estrogen-receptor ligand.

FAAH Inhibition & the Endocannabinoid Angle

Biochanin A’s most distinctive mechanism has nothing to do with estrogen. It is a naturally occurring inhibitor of fatty acid amide hydrolase (FAAH) — the enzyme that breaks down the endocannabinoid anandamide — with IC₅₀ values of roughly 1.4–2.4 μM against mouse, rat and human FAAH ^{3Reference 3Thors L et al. · 2010Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolaseView study →}. By slowing anandamide’s degradation, FAAH inhibition raises endocannabinoid tone, the same target pursued by a class of experimental analgesic and anxiolytic drugs.

Importantly, biochanin A does this without directly activating the cannabinoid receptors CB1 or CB2, and without touching the related enzyme FAAH-2 — so it works by preserving the body’s own endocannabinoids rather than acting as a cannabinoid itself ^{3Reference 3Thors L et al. · 2010Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolaseView study →}. Screening of isoflavonoids for antidepressant potential put biochanin A among the more promising FAAH inhibitors (alongside 7-hydroxyflavone and genistein), raising brain anandamide in rodent behavioural work ^{4Reference 4Zada W et al. · 2022Fatty acid amide hydrolase inhibition and N-arachidonoylethanolamine modulation by isoflavonoids: a novel target for upcoming antidepressantsView study →}.

This endocannabinoid route plausibly underlies some of biochanin A’s analgesic signal: in a rat model it attenuated diabetic neuropathic pain ^{13Reference 13Chundi V et al. · 2016AnimalBiochanin-A attenuates neuropathic pain in diabetic rats — rat in vivoView study →}. It is a genuinely compound-flavoured mechanism — an isoflavone moonlighting on the endocannabinoid system — but it remains a preclinical finding, established in enzyme assays and rodents, not in people.

What It's Used For

Outside the whole-extract menopause data, biochanin A’s evidence is isolated-molecule work, overwhelmingly in cells and rodents. Read each row for the tier it actually rests on, and hold the pharmacokinetic ceiling (poor oral bioavailability, extensive first-pass demethylation/conjugation) under all of it ^{5Reference 5Moon YJ · 2007AnimalPharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in ratsView study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume, tempered for isolate-vs-plant match and bioavailability. A beta, not a validated metric. The estrogenic row mixes genuine human (whole-extract) data with the honest problem that biochanin A is only one isoflavone in that extract; every other row is preclinical. Each application links to its write-up.

01Menopausal & Estrogenic SymptomsPromising46%Red-clover extract RCT meta-analysis (isoflavone mixture) + ovx-rat bone data ^{7,11,12Reference 7Kanadys W et al. · 2021Meta-analysisEvaluation of clinical meaningfulness of red clover (Trifolium pratense L.) extract to relieve hot flushes and menopausal symptoms in peri- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trialsView study →Reference 11Su SJ et al. · 2013AnimalThe preventive effect of biochanin A on bone loss in ovariectomized rats: involvement in regulation of growth and activity of osteoblasts and osteoclasts — rat in vivoView study →Reference 12Su SJ et al. · 2013In vitroBiochanin A promotes osteogenic but inhibits adipogenic differentiation: evidence with primary adipose-derived stem cells — in vitroView study →}

02Anticancer (Aromatase / Antiproliferative)Shaky34%Breast-cancer cell lines; aromatase activity + expression inhibited ^{1Reference 1Wang Y et al. · 2008In vitroThe red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression — in vitroView study →}

03Anti-Inflammatory & Analgesic (FAAH / PDE4)Shaky32%Enzyme assays + rodent airway / neuropathic-pain models ^{3,4,6,13Reference 3Thors L et al. · 2010Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolaseView study →Reference 4Zada W et al. · 2022Fatty acid amide hydrolase inhibition and N-arachidonoylethanolamine modulation by isoflavonoids: a novel target for upcoming antidepressantsView study →Reference 6Ko WC et al. · 2011AnimalBiochanin A, a phytoestrogenic isoflavone with selective inhibition of phosphodiesterase 4, suppresses ovalbumin-induced airway hyperresponsiveness — mouse in vivoView study →Reference 13Chundi V et al. · 2016AnimalBiochanin-A attenuates neuropathic pain in diabetic rats — rat in vivoView study →}

04NeuroprotectionShaky30%Rat / in-vitro Parkinson’s models; microglial suppression ^{8,9Reference 8Chen HQ et al. · 2007In vitroBiochanin A protects dopaminergic neurons against lipopolysaccharide-induced damage through inhibition of microglia activation and proinflammatory factors generation — rat / in vitroView study →Reference 9Wang J et al. · 2016In vitroBiochanin A protects against lipopolysaccharide-induced damage of dopaminergic neurons both in vivo and in vitro via inhibition of microglial activationView study →}

05Metabolic / AntidiabeticShaky27%Rat type-2-diabetes model; PPAR-γ / AMPK ^{10Reference 10Oza MJ · 2018AnimalBiochanin A improves insulin sensitivity and controls hyperglycemia in type 2 diabetes — rat in vivoView study →}

Mechanisms

The through-line is that biochanin A is really two things at once: an intact molecule with its own enzyme targets (aromatase, FAAH, PDE4) and a methyl-ether precursor slowly releasing genistein — so its estrogenic and its enzyme-inhibiting profiles belong partly to different chemical species.

Pharmacokinetics

Pharmacokinetics is the ceiling on this whole page. Biochanin A’s oral bioavailability is poor — roughly 1–2% in male and 4–5% in female rats — largely because of low aqueous solubility and heavy first-pass handling ^{5Reference 5Moon YJ · 2007AnimalPharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in ratsView study →}. Two processes act on an absorbed dose: O-demethylation to genistein (cytochrome-P450-mediated, shown in human liver microsomes) ^{2Reference 2Tolleson WH et al. · 2002In vitroMetabolism of biochanin A and formononetin by human liver microsomes in vitroView study →}, and extensive conjugation — glucuronidation and sulfation — to inactive metabolites that undergo enterohepatic recycling ^{5Reference 5Moon YJ · 2007AnimalPharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in ratsView study →}. Because dietary flavonoids compete for the same conjugating enzymes and efflux transporters, co-administered quercetin and EGCG raised biochanin A bioavailability several-fold in rats ^{5Reference 5Moon YJ · 2007AnimalPharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in ratsView study →}. Net effect: circulating free biochanin A after an oral dose is low and short-lived, part of it appearing as genistein, so the micromolar potencies in cell culture overstate what an oral human dose would reach.

Clinical Trials

There are no registered trials of isolated biochanin A. The only human evidence touching it is for whole red-clover extract in menopausal symptoms, where biochanin A is one isoflavone among several ^{7Reference 7Kanadys W et al. · 2021Meta-analysisEvaluation of clinical meaningfulness of red clover (Trifolium pratense L.) extract to relieve hot flushes and menopausal symptoms in peri- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trialsView study →}; every other application is preclinical.

Last checked: July 2026.

Isolate vs. Plant Studies

Biochanin A splits cleanly by tier. The human data are plant, not isolate: red-clover extract has randomised-trial and meta-analytic support for menopausal hot flushes, but it is an isoflavone mixture (biochanin A + formononetin, plus the genistein/daidzein they generate), so the clinical benefit cannot be assigned to biochanin A alone — even though higher-biochanin-A formulations did better ^{7Reference 7Kanadys W et al. · 2021Meta-analysisEvaluation of clinical meaningfulness of red clover (Trifolium pratense L.) extract to relieve hot flushes and menopausal symptoms in peri- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trialsView study →}. The mechanistic data are isolate: aromatase inhibition ^{1Reference 1Wang Y et al. · 2008In vitroThe red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression — in vitroView study →}, FAAH and PDE4 inhibition ^{3,6Reference 3Thors L et al. · 2010Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolaseView study →Reference 6Ko WC et al. · 2011AnimalBiochanin A, a phytoestrogenic isoflavone with selective inhibition of phosphodiesterase 4, suppresses ovalbumin-induced airway hyperresponsiveness — mouse in vivoView study →}, the neuroprotective microglial work ^{8,9Reference 8Chen HQ et al. · 2007In vitroBiochanin A protects dopaminergic neurons against lipopolysaccharide-induced damage through inhibition of microglia activation and proinflammatory factors generation — rat / in vitroView study →Reference 9Wang J et al. · 2016In vitroBiochanin A protects against lipopolysaccharide-induced damage of dopaminergic neurons both in vivo and in vitro via inhibition of microglial activationView study →} and the metabolic model ^{10Reference 10Oza MJ · 2018AnimalBiochanin A improves insulin sensitivity and controls hyperglycemia in type 2 diabetes — rat in vivoView study →} all used purified biochanin A, which is why those mechanisms are cleanly attributable to this molecule. The bridge between them is weak in one direction — the poor bioavailability and in-vivo demethylation ^{2,5Reference 2Tolleson WH et al. · 2002In vitroMetabolism of biochanin A and formononetin by human liver microsomes in vitroView study →Reference 5Moon YJ · 2007AnimalPharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in ratsView study →} mean neither the isolate mechanisms nor the whole-extract human results transfer confidently to the other.

Prevalence in Nature

Biochanin A is characteristically a legume (Fabaceae) isoflavone. Its signature source is red clover (Trifolium pratense), where together with formononetin it is one of the two dominant isoflavones of the flowering tops — measured at 0.69–6.44 mg/g dry weight (~0.07–0.64%) across fourteen cultivars, a several-fold cultivar-dependent range ^{14Reference 14Gościniak A et al. · 2026Red clover isoflavones as effective longevity agents for anti-aging and regenerative skin applications (fourteen-cultivar formononetin / biochanin A content) — analyticalView study →}. It is also a major isoflavone of chickpea (Cicer arietinum), and occurs in soy, alfalfa and other legumes, generally as the methylated counterpart to genistein. In red clover the native content of free genistein/daidzein is low; the plant stores the methyl ethers (biochanin A, formononetin) and the demethylated phytoestrogens are largely produced after ingestion ^{2,7Reference 2Tolleson WH et al. · 2002In vitroMetabolism of biochanin A and formononetin by human liver microsomes in vitroView study →Reference 7Kanadys W et al. · 2021Meta-analysisEvaluation of clinical meaningfulness of red clover (Trifolium pratense L.) extract to relieve hot flushes and menopausal symptoms in peri- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trialsView study →}.

Its place in the plant’s chemistry follows one biosynthetic step: the isoflavonoid pathway 4’-O-methylates genistein to give biochanin A (as it methylates daidzein to formononetin), so the methylated and demethylated isoflavones always travel together, with biochanin A upstream of genistein.

Discovery & Synthesis

Biochanin A (CAS 491-80-5) is 5,7-dihydroxy-4’-methoxyisoflavone — the 4’-methyl ether of genistein — and has long been characterised as a principal isoflavone of red clover and chickpea. Its metabolic identity was pinned down early: the in-vivo O-demethylation of biochanin A to genistein was documented in the rat by the early 1960s, and later confirmed in human liver microsomes as a P450-mediated reaction ^{2Reference 2Tolleson WH et al. · 2002In vitroMetabolism of biochanin A and formononetin by human liver microsomes in vitroView study →}. The first total chemical synthesis is not well documented in the modern literature; for research the compound is obtained overwhelmingly by extraction and purification from red clover or chickpea, or by O-methylation of genistein, rather than by manufacture from scratch.

Patents: not yet researched.

Toxicity & Safety

Biochanin A carries a low flag. It is a dietary-type isoflavone eaten for centuries as part of clover-fed dairy, chickpea and soy, its oral bioavailability is intrinsically poor ^{5Reference 5Moon YJ · 2007AnimalPharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in ratsView study →}, and the preclinical safety literature is broadly favourable. The meaningful caution is not general toxicity but its hormonal activity.

Biochanin A is a phytoestrogen, both directly and through its genistein metabolite ^{1,2Reference 1Wang Y et al. · 2008In vitroThe red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression — in vitroView study →Reference 2Tolleson WH et al. · 2002In vitroMetabolism of biochanin A and formononetin by human liver microsomes in vitroView study →}. As with the whole isoflavone class, its estrogen-receptor activity is biphasic and dose-dependent: potentially estrogen-antagonistic / anti-proliferative at the higher concentrations used in cancer studies, but weakly estrogen-agonistic at low exposure ^{1Reference 1Wang Y et al. · 2008In vitroThe red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression — in vitroView study →}. That makes concentrated red-clover / isoflavone supplements a reasonable point of individual caution in hormone-sensitive conditions (e.g. oestrogen-receptor-positive breast cancer, endometrial concerns), and any reproductive or developmental consideration for a concentrated phytoestrogen is a whole-preparation decision made on the herb or product page, not settled here. Notably, a dedicated human study of red clover found no clinically relevant CYP450 inhibition at 120 mg isoflavones/day, so the commonly repeated drug-interaction warning is not well supported for the extract; the isolate’s FAAH/PDE4 activity ^{3,6Reference 3Thors L et al. · 2010Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolaseView study →Reference 6Ko WC et al. · 2011AnimalBiochanin A, a phytoestrogenic isoflavone with selective inhibition of phosphodiesterase 4, suppresses ovalbumin-induced airway hyperresponsiveness — mouse in vivoView study →} is the more plausible (but still theoretical, preclinical) place a future interaction would be looked for. Documented human drug-interaction data for isolated biochanin A are lacking.

Safety at a Glance

✅ Low / no toxicity

• Low intrinsic toxicity. A dietary isoflavone with poor oral bioavailability; centuries of exposure via clover, chickpea and soy.
• Phytoestrogen — biphasic. Weakly estrogenic at low exposure, anti-proliferative at high; concentrated isoflavone intake warrants individual caution in hormone-sensitive conditions.
• Reproductive decisions belong to the herb/product page. Any pregnancy/lactation or hormone-sensitive-cancer judgement is a whole-preparation call, not a molecule-level one.
• Interaction signals are preclinical. The FAAH/PDE4 activity is a theoretical interaction site; whole red clover showed no clinically relevant CYP450 inhibition at 120 mg/day.

Dosage

There is no established human dose for isolated biochanin A, and its poor bioavailability means research doses do not translate into an oral human regimen. Human exposure occurs as one isoflavone within whole red-clover extract: standardised products (e.g. the Promensil/Rimostil family) deliver roughly 40–80 mg total isoflavones per tablet, of which biochanin A is a portion alongside formononetin, genistein and daidzein, and the menopause trials used ≥80 mg/day total isoflavones over ~12 weeks ^{7Reference 7Kanadys W et al. · 2021Meta-analysisEvaluation of clinical meaningfulness of red clover (Trifolium pratense L.) extract to relieve hot flushes and menopausal symptoms in peri- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trialsView study →}. For research context only, the studies above used purified biochanin A at low-micromolar concentrations in cell culture ^{1,3Reference 1Wang Y et al. · 2008In vitroThe red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression — in vitroView study →Reference 3Thors L et al. · 2010Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolaseView study →} and by oral or injected dosing in rodents ^{6,10Reference 6Ko WC et al. · 2011AnimalBiochanin A, a phytoestrogenic isoflavone with selective inhibition of phosphodiesterase 4, suppresses ovalbumin-induced airway hyperresponsiveness — mouse in vivoView study →Reference 10Oza MJ · 2018AnimalBiochanin A improves insulin sensitivity and controls hyperglycemia in type 2 diabetes — rat in vivoView study →} — levels and routes not achievable by ordinary dietary intake. These are doses studied in research and are not a personal recommendation.

References

1. Wang Y, Man Gho W, Chan FL, Chen S, Leung LK (2008). The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression — in vitro. British Journal of Nutrition. https://pubmed.ncbi.nlm.nih.gov/17761019/
2. Tolleson WH, Doerge DR, Churchwell MI, Marques MM, Roberts DW (2002). Metabolism of biochanin A and formononetin by human liver microsomes in vitro. Journal of Agricultural and Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/12166960/
3. Thors L, Burston JJ, Alter BJ, McKinney MK, Cravatt BF, Ross RA, Pertwee RG, Gereau RW 4th, Wiley JL, Fowler CJ (2010). Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase. British Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/20590565/
4. Zada W, VanRyzin JW, Perez-Pouchoulen M, Baglot SL, et al. (2022). Fatty acid amide hydrolase inhibition and N-arachidonoylethanolamine modulation by isoflavonoids: a novel target for upcoming antidepressants. Pharmacology Research & Perspectives. https://pubmed.ncbi.nlm.nih.gov/36029006/
5. Moon YJ, Morris ME (2007). Pharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in rats. Molecular Pharmaceutics. https://pubmed.ncbi.nlm.nih.gov/17970592/
6. Ko WC, Lin LH, Shen HY, Lai CY, Chen CM, Shih CH (2011). Biochanin A, a phytoestrogenic isoflavone with selective inhibition of phosphodiesterase 4, suppresses ovalbumin-induced airway hyperresponsiveness — mouse in vivo. Evidence-Based Complementary and Alternative Medicine. https://pubmed.ncbi.nlm.nih.gov/21437195/
7. Kanadys W, Barańska A, Błaszczuk A, Polz-Dacewicz M, Drop B, Malm M, Kanecki K (2021). Evaluation of clinical meaningfulness of red clover (Trifolium pratense L.) extract to relieve hot flushes and menopausal symptoms in peri- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. Nutrients. https://pubmed.ncbi.nlm.nih.gov/33920485/
8. Chen HQ, Jin ZY, Li GH (2007). Biochanin A protects dopaminergic neurons against lipopolysaccharide-induced damage through inhibition of microglia activation and proinflammatory factors generation — rat / in vitro. Neuroscience Letters. https://pubmed.ncbi.nlm.nih.gov/17399896/
9. Wang J, Wu WY, Huang H, Li WZ, Chen HQ, Yin YY (2016). Biochanin A protects against lipopolysaccharide-induced damage of dopaminergic neurons both in vivo and in vitro via inhibition of microglial activation. Neurotoxicity Research. https://pubmed.ncbi.nlm.nih.gov/27417698/
10. Oza MJ, Kulkarni YA (2018). Biochanin A improves insulin sensitivity and controls hyperglycemia in type 2 diabetes — rat in vivo. Biomedicine & Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/30257324/
11. Su SJ, Yeh YT, Shyu HW (2013). The preventive effect of biochanin A on bone loss in ovariectomized rats: involvement in regulation of growth and activity of osteoblasts and osteoclasts — rat in vivo. Evidence-Based Complementary and Alternative Medicine. https://pubmed.ncbi.nlm.nih.gov/23533501/
12. Su SJ, Yeh YT, Su SH, Chang KL, Shyu HW, Chen KM, Yeh H (2013). Biochanin A promotes osteogenic but inhibits adipogenic differentiation: evidence with primary adipose-derived stem cells — in vitro. Evidence-Based Complementary and Alternative Medicine. https://pubmed.ncbi.nlm.nih.gov/23843885/
13. Chundi V, Challa SR, Garikapati DR, Juvva G, Jampani A, Pinnamaneni SH, Venigalla S (2016). Biochanin-A attenuates neuropathic pain in diabetic rats — rat in vivo. Journal of Ayurveda and Integrative Medicine. https://pubmed.ncbi.nlm.nih.gov/27890700/
14. Gościniak A, Bogusławska K, Szymańska M, Kaproń-Plech B, Trzaskoma P, Szulc P, Cielecka-Piontek J (2026). Red clover isoflavones as effective longevity agents for anti-aging and regenerative skin applications (fourteen-cultivar formononetin / biochanin A content) — analytical. Plants. https://pubmed.ncbi.nlm.nih.gov/41754260/

View all 14 references▾